Slide 1: Second Quarter 2025 Financial Results
August 12, 2025 Second Quarter 2025 Financial Results
Slide 2: Welcome and Participants
Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Jeffrey Creech Executive Vice President & Chief Financial Officer Mick McCloskey Vice President, Treasury & Investor Relations To participate via phone, please dial: 1-201-689-8345 2
Slide 3: Forward Looking Statements
Forward Looking Statements Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncert
Slide 4: Dr. Jeffrey Graves
Dr. Jeffrey Graves President & Chief Executive Officer 4
Slide 5: Strong Focus on Execution; Strategic Markets Continue to Thrive
Strong Focus on Execution • Sequential strengthening despite continued macroeconomic challenges for our industry • “Controlling the controllables”, delivering on our restructuring plans on the path to sustainable profitability Strategic Markets Continue to Thrive Against Broader Top-Line Challenges
Slide 6: Cost Reduction & Profitability Improvement Initiatives
Cost Reduction & Profitability Improvement Initiatives Initiatives target over $85mm of annualized savings planned through 1H’26 Savings to date are primary driver for YoY and QoQ reductions in OpEx Organizational Capacity Business & Legal Entity External & Professional Service COGS Optimization Sit
Slide 7: Unmatched Capability in AM for Healthcare Solutions
Unmatched Capability in AM for Healthcare Solutions Dental Medical Technologies Regenerative Medicine Foundational and Fastest growing opportunity Unapparelled opportunity industry leading legacy to continue winning with exponential growth short/medium term long-term • Straighten • Repair • Personal
Slide 8: Compelling Growth in Medical Technologies
Compelling Growth in Medical Technologies • Medical Technologies, or “MedTech”, includes • “Above-the-neck” is our largest and fastest personalized healthcare, point of care, healthcare growing vertical. Leverages legacy strengths and part manufacturing, printers, materials and highly customizable n
Slide 9: Delivering the "3P's"
Delivering the “3P’s” Following Process…customers in high-reliability industries can leverage Parts production as a bridge, then scale to capital investment for Printers •Review – •Scale explore, define production & efficiency •Capital •Develop – investment in Process design, validate Parts •High va
Slide 10: Mapping our Strategy to Critical Industrial Markets
Mapping our Strategy to Critical Industrial Markets 10
Slide 11: Compelling Growth Opportunity in Digital Dentistry
Compelling Growth Opportunity in Digital Exceptional Customer Feedback Dentistry Through Beta Testing Targeting a 2029E $600mm “Replace” addressable market in the US with our FDA- “Because of the NextDent 300’s post-processing workflow, we are able to make cleared multi-material monolithic jetted de
Slide 12: Jeffrey Creech
Jeffrey Creech Chief Financial Officer 12
Slide 13: Q2 Revenue Summary
Q2 Revenue Summary ($ in millions) • Industrial softness in consumer- Q2’24 Q1’25 Q2’25 facing markets partially offset by 84% YoY growth in Aerospace & As Reported Defense (A&D); QoQ rebound (excluding Geomagic) driven largely Industrial Solutions $64 $53 $50 by A&D strength Healthcare Solutions $4
Slide 14: Gross Profit Margin
Gross Profit Margin (Non-GAAP) 40.9% 39.2% Second Quarter Drivers 38.1% • QoQ improvement primarily attributed to favorable 35.0% manufacturing variances from higher volume and cost efficiency plans • ~$2mm of benefit associated with milestone recognition in Regenerative Medicine Q2'24 Q2'24 Adj. Q1
Slide 15: Operating Expense
Operating Expense (Non-GAAP) ($ in millions) Second Quarter Drivers Significant OpEx Reductions • YoY & QoQ improvements of 27% & 24%, $17mm YoY respectively $15mm QoQ • Reflects significant savings delivered through restructuring – with meaningful efficiencies across nearly all functions and $64 ge
Slide 16: Earnings
Earnings ($ in millions, except per share amounts) Q2’24 Q2’25 Net Income ($27.3) $104.4 Q2 Profitability Drivers • Primarily driven by cost reduction initiatives yielding GAAP EPS ($0.21) $0.57 significant improvement in operating expense • Gains recognized on Geomagic asset sale and proactive Adj.
Slide 17: Balance Sheet Highlights
Balance Sheet Highlights • Ended the quarter with ~$134 million of cash, cash equivalents and restricted cash • Completed sale of Geomagic business for nearly $120 million in cash on April 1, 2025 • June debt transaction permanently retires $88 million in debt at discount to par, extending $92 milli
Slide 18: Q&A Session
Q&A Session 1-201-689-8345 18
Slide 19: Thank You
Thank You Find out more at: www.3dsystems.com 19
Slide 20: Appendix
Appendix ©2025 3D Systems, Inc. | All Rights Reserved.
Slide 21: Presentation of Information
Presentation of Information 3D Systems reports its financial results in accordance with GAAP. Management also reviews and reports certain Non-GAAP measures, including: Non-GAAP revenue excluding divestitures and on a constant currency basis (sometimes referred to as excluding divestitures and FX eff
Slide 22: Unaudited Reconciliations of GAAP to Non-GAAP Measures
Appendix 3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures Non-GAAP Gross Profit and Gross Profit Margin (unaudited) Three Months Ended (in millions) June 30, 2025 June 30,2024 Gross Profit Sergi Gross Profit py Gross profit (GAAP) $ 36.2 38.1% $ 471 41.6% Amortization ex
Slide 23: Net Income (Loss) to Adjusted EBITDA Reconciliation
Appen 3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures ‘Net Income (Loss) Attributable to 3D Systems Corporation to Adjusted EBITDA (unaudited) ‘Three Months Ended Six Months Ended Ginmitions) June 30,2025 June 30.2024 June 30,202 __ June 30,2024 Net income (loss) attrib